Every weekday, the CNBC Investing Club with Jim Cramer hosts a “Morning Meeting” livestream at 10:20 a.m. ET. Here's a recap of Tuesday's key moments. 1. US stocks plunged on Tuesday on better-than-expected retail inflation data. January's surprise rally in the consumer price index sent bond yields higher, with the Dow, S&P 500 and Nasdaq down more than 1% each. Frankly, we're not surprised to see the stock pull back because the market is up 14 of the last 15 weeks. The new CPI data puts market expectations around interest rate cuts more in line with the Federal Reserve's commentary. Good news for the Club: we have a great cash position. If this decline were to continue, it could present another buying opportunity. However, for now we will be patient. 2. Wall Street continued to praise Palo Alto Networks. Analysts at Jefferies raised their price target on the cybersecurity name to $450 per share from $350. Analysts at Stifel raised theirs to $410 from $280. Research analysts at both companies cited strong channel controls ahead of the cybersecurity leader's quarterly earnings release next week. Jefferies said the biggest risk in Palo Alto right now is its 29% year-to-date gains, which far outpace the S&P 500's roughly 4% gain. The stock has more than doubled in 2023. Like analysts in general, we believe Palo Alto has an excellent setup for the year, given the growing demand for cybersecurity offerings. 3. Jefferies raised Eli Lilly's price target to $853 per share from $815. Analysts are increasingly confident in the safety profile of orforglipron, the company's GLP-1 weight loss and diabetes pill that is in the process of testing the drug. This is critical to its commercial future because Pfizer discontinued one of its experimental GLP-1 pills last year due to toxicity concerns. In addition to the quarterly earnings, Eli Lilly said it plans to increase supply of orforglipron ahead of approval because it sees a big opportunity. We are optimistic about this because the company has a track record of making the right decisions, both in terms of effectiveness and safety. If Lilly stock wasn't rising in Tuesday's bear market, we would consider buying more, given the strong fundamentals and serious growth prospects. The market-leading GLP-1s (Lilly's Zepbound and Mounjaro, and Novo Nordisk's Ozempic and Wegovy) are injectables (Jim Cramer's Charitable Trust is long PANW, LLY. See here for a full list of stocks). As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable fund's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTMENT CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY, TOGETHER WITH OUR DISCLAIMER. NO FIDUCIARY OBLIGATION OR DUTY EXISTS OR IS CREATED BY VIRTUE OF THE RECEIPT OF ANY INFORMATION PROVIDED IN RELATION TO THE INVESTMENT CLUB. NO SPECIFIC RESULTS OR BENEFITS ARE GUARANTEED.
